...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Reversal of Morphine Antinociceptive Tolerance and Dependence by the Acute Supraspinal Inhibition of Ca~(2+)/Calmodulin-Dependent Protein Kinase II
【24h】

Reversal of Morphine Antinociceptive Tolerance and Dependence by the Acute Supraspinal Inhibition of Ca~(2+)/Calmodulin-Dependent Protein Kinase II

机译:通过对Ca〜(2 +)/钙调蛋白依赖性蛋白激酶II的急性Suspaspinal抑制来逆转吗啡的抗伤害感受性耐受性和依赖性。

获取原文
获取原文并翻译 | 示例

摘要

Previous studies have suggested that Ca~(2+)/calmodulin-depen-dent protein kinase II (CaMKII) can modulate opioid tolerance and dependence via its action on learning and memory.In this study,we examined whether CaMKII could directly regulate opioid tolerance and dependence.CaMKII activity was increased after the treatment with morphine (100 mg/kg s.c.or 75 mg s.c.of morphine/pellet/mouse);the effect exhibited a temporal correction with the development of opioid tolerance and dependence.In mice treated with morphine (100 mg/kg s.c.),morphine tolerance and dependence developed in 2 to 6 h.An acute supraspinal administration of KN93 [2-[N-(2-hydro-xyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocin-namyl)-N-methylbenzylamine)],a CaMKII inhibitor,was able to dose-dependently reverse the already-established antinoci-ceptive tolerance to morphine (p < 0.001 for 15-30 nmol;not significant for 5 nmol).KN92 [2-[N-(4-methoxybenzenesul-fonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine] (30 nmol i.c.v.),a kinase-inactive analog of KN93,did not affect opioid tolerance.Neither KN92 nor KN93 affected basal noci-ception or acute morphine antinociception (1-10 nmol i.c.v.).Likewise,dependence on morphine was abolished by the acute administration of KN93,but not KN92,in a dose-dependent manner.Pretreatment of mice with KN93 also prevented the development of morphine tolerance and dependence.The effect of acute CaMKII inhibition was not limited to the particular experimental model,because KN93 also acutely reversed the established opioid tolerance and dependence in mice treated with morphine (75 mg/pellet/mouse s.c.) for 6 days.Taken together,these data strongly support the hypothesis that CaMKII can act as a key and direct factor in promoting opioid tolerance and dependence.Identifying such a direct mechanism may be useful for designing pharmacological treatments for these conditions.
机译:以前的研究表明Ca〜(2 +)/钙调蛋白依赖性蛋白激酶II(CaMKII)可以通过其对学习和记忆的作用来调节阿片样物质的耐受性和依赖性。在这项研究中,我们研究了CaMKII是否可以直接调节阿片样物质的耐受性吗啡处理后(100 mg / kg scor 75 mg scof吗啡/丸/小鼠)CaMKII活性增加;随着阿片类药物耐受性和依赖性的发展,该作用表现出暂时的校正作用。 (100 mg / kg sc),吗啡耐受性和依赖性在2到6小时内出现。急性脊髓上神经节给药KN93 [2- [N-(2-氢-二乙基)]-N-(4-甲氧基苯磺酰基)氨基- CaMKII抑制剂N-(4-chlorocin-namyl)-N-甲基苄胺)能够剂量依赖性地逆转已建立的对吗啡的镇痛药耐受性(对于15-30 nmol,p <0.001;对于5 nmol).KN92 [2- [N-(4-甲氧基苯磺酰)]氨基-N-(4-氯肉桂基)-N-甲基苄胺](30 nmol icv),一种激酶失活的KN93类似物,不会影响阿片类药物的耐受性。KN92和KN93均不影响基础痛觉或急性吗啡镇痛作用(1-10 nmol icv)。同样,对吗啡的依赖性已被消除急性剂量的KN93而非KN92急性给药。用KN93预处理小鼠还可以防止吗啡耐受性和依赖性的发展。急性CaMKII抑制作用不仅限于特定的实验模型,因为KN93也急性逆转了吗啡(75 mg /丸/小鼠皮下注射)对小鼠的阿片类药物耐受性和依赖性已建立的6天。综上所述,这些数据强烈支持了CaMKII可以作为促进阿片类药物耐受性的关键和直接因素的假设。识别这种直接机制可能对设计针对这些疾病的药物治疗有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号